Semaglutide is not banned in Mississippi. FDA-approved versions of the drug, including the brand-name injections and tablets prescribed for type 2 diabetes and weight management, remain fully legal and available by prescription through licensed providers and pharmacies in the state. What Mississippi has restricted is pharmacy compounding of semaglutide, especially compounded products made with unapproved chemical salt forms of the drug. That restriction, combined with a federal decision that the national semaglutide shortage is over, has sharply cut the supply of cheaper compounded alternatives and left many patients thinking the drug itself is illegal here. It isn’t.
What Mississippi Has Actually Restricted
The limits apply to compounding, not to the drug. Compounding is when a pharmacist mixes a customized version of a medication for a specific patient. Mississippi allows it only under narrow conditions, mainly when the commercially manufactured version of a drug is unavailable or doesn’t meet a particular patient’s medical needs.1Mississippi Board of Pharmacy. Mississippi Pharmacy Practice Regulations – Article XXXI Compounding Guidelines A pharmacy can prepare a copy of a commercial product only when that product is on the FDA drug shortage list or has been discontinued by its manufacturer.
Because FDA-approved semaglutide injections are commercially available again and no longer in shortage, the window for pharmacies to legally compound copycat versions has effectively closed. The Mississippi State Board of Pharmacy has also made clear that any compounded order needs patient-specific medical justification, backed by a valid prescription explaining why the standard commercial product won’t work for that patient.
The second piece of the restriction is about ingredients. Some compounding pharmacies have used semaglutide sodium or semaglutide acetate, which are salt forms of the molecule and chemically distinct from the base form of semaglutide used in approved drugs like Ozempic and Wegovy. The FDA has stated that these salt forms are different active ingredients and that the agency lacks data on whether they share the same properties as the approved drug.2FDA. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss Mississippi pharmacists cannot use these salt forms in any compounded medication. Because semaglutide sodium and semaglutide acetate don’t appear in any FDA-approved product, they don’t qualify as legitimate bulk drug substances for compounding at all.
This distinction is where most of the “semaglutide ban” headlines come from. The reality is more technical than a blanket prohibition: the specific ingredients used in many compounded weight-loss shots were never approved for human use to begin with.
Why Compounded Versions Disappeared
For a stretch of time, semaglutide injection products were on the FDA’s official drug shortage list, which gave pharmacies more latitude under federal law to compound the drug even when the result was essentially a copy of the commercially available version. That changed in February 2025, when the FDA determined the shortage was resolved and confirmed the manufacturer had enough supply and manufacturing capacity to meet national demand.3FDA. FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize
The agency gave pharmacies a short transition window. State-licensed pharmacies compounding under federal Section 503A had until April 22, 2025. Outsourcing facilities operating under Section 503B had until May 22, 2025. After those dates, compounding semaglutide as a copy of the approved product became a federal violation, not just a state one.
There is one nuance worth knowing. The FDA’s enforcement applies to products that are “essentially a copy” of an approved drug. A compounded semaglutide product with a genuinely different formulation, such as a different dose or different inactive ingredients tailored to an individual patient’s documented needs, may still be permissible under Section 503A. The product just cannot mirror what’s already on pharmacy shelves at a lower price. Semaglutide also does not appear on the FDA’s 503B bulks list, so outsourcing facilities cannot use semaglutide bulk drug substance for compounding unless the drug returns to the shortage list.
How to Legally Get Semaglutide in Mississippi
The legal path is straightforward. Get a prescription from a licensed healthcare provider and fill it at a licensed pharmacy that sources from authorized wholesalers. Physicians and advanced practice registered nurses with proper collaborative agreements can prescribe the medication.4Legal Information Institute. 30 Mississippi Code R 2840-1.5 – Prescribing Controlled Substances and Medications by APRNs The prescription has to be based on a legitimate medical evaluation and documented medical need.
Mississippi also permits telehealth prescribing, which matters because many patients first explore weight-loss drugs through online platforms. State law allows a provider to prescribe after an appropriate examination conducted either in person or through technology that transmits images and medical records electronically, as long as the remote exam meets the same standard of care as a face-to-face visit. One hard rule: a prescription based only on an online questionnaire is not valid in Mississippi. A real-time evaluation with a licensed provider is required.
What It Costs
Cost is why compounded semaglutide got popular, and it’s the biggest pain point now that those alternatives are off the table. The FDA-approved products are more expensive than compounded versions were. Novo Nordisk, the maker of Wegovy, offers several pricing tiers for patients in 2026:
- With commercial insurance: as low as $25 per month through the manufacturer’s savings program, with maximum savings of $100 per month.
- Self-pay at the 1.5 mg dose: starting at $149 per month.
- Self-pay at lower doses: starting at $199 per month, with an introductory offer of $199 for the first two months on 0.25 mg or 0.5 mg doses, then $349 per month.
These prices apply to a 28-day supply of the Wegovy pen or a 30-day supply of the Wegovy pill.5Wegovy. What to Pay for Wegovy Novo Nordisk can modify or cancel these programs at any time, so check the current terms before counting on a specific price.
For Medicare beneficiaries, a change takes effect on July 1, 2026. A temporary program called the Medicare GLP-1 Bridge will provide limited coverage for weight-loss medications, including Wegovy, for eligible Part D plan members diagnosed with obesity who show a documented medical need for drug treatment. Eligible beneficiaries will pay a $50 copay for each 30-day supply. The Bridge program runs through December 31, 2027. Standard Medicare Part D plans still do not cover GLP-1 medications prescribed solely for weight loss, though they may cover Ozempic or Wegovy when prescribed for diabetes management or cardiovascular disease.
If You’re Currently On Compounded Semaglutide
Talk to your prescribing provider about transitioning to an FDA-approved version. The abrupt end of the compounding window caught many patients off guard, and stopping a GLP-1 medication suddenly can cause rebound weight gain and blood sugar fluctuations. Your provider can help manage the transition timing and dosing so the switch doesn’t undo the progress you’ve made.
If a pharmacy in Mississippi is still offering compounded semaglutide, especially at prices well below the manufacturer’s self-pay tiers, that’s a warning sign worth taking seriously. Ask what form of semaglutide is being used, where the active ingredient was sourced, and under what justification the pharmacy is compounding rather than dispensing the approved product. A legitimate answer should reference a specific patient-specific medical need, not a general price advantage.